Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan C Lynch

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Current Biology : CB|January 1, 2008
TORC1 is essential for NF1-associated malignanciesCory M Johannessen, Bryan W Johnson, Sybil M Genther Williams, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2006
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switchSylvie Giuriato, Sandra Ryeom, Alice C Fan, et al.
Microbiology and Molecular Biology Reviews : MMBR|September 6, 2013
Patterns and processes of microbial community assemblyDiana R Nemergut, Steven K Schmidt, Tadashi Fukami, et al.
Journal of the National Cancer Institute|July 7, 2016
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States VeteransDaphne Y Xiao, Suhong Luo, Katiuscia O'Brian, et al.
BMC Immunology|September 17, 2004
Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organsYulei Shen, Javeed Iqbal, Li Xiao, et al.
British Journal of Haematology|October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphomaRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
American Journal of Hematology|June 17, 2026
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell LymphomaStephen D Smith, Suchitra Sundaram, Sharmila Giri, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 24, 2025
Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell LymphomaCarrie Ho, Neena Kennedy, Mengyang Di, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 28, 2020
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell LymphomaSolomon A Graf, Ryan D Cassaday, Karolyn Morris, et al.
JCO Oncology Practice|November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World ExperienceIvan J Huang, Grace T Baek, Jonathan Cohen, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Current Biology : CB|January 1, 2008
TORC1 is essential for NF1-associated malignanciesCory M Johannessen, Bryan W Johnson, Sybil M Genther Williams, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2006
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switchSylvie Giuriato, Sandra Ryeom, Alice C Fan, et al.
Microbiology and Molecular Biology Reviews : MMBR|September 6, 2013
Patterns and processes of microbial community assemblyDiana R Nemergut, Steven K Schmidt, Tadashi Fukami, et al.
Journal of the National Cancer Institute|July 7, 2016
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States VeteransDaphne Y Xiao, Suhong Luo, Katiuscia O'Brian, et al.
BMC Immunology|September 17, 2004
Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organsYulei Shen, Javeed Iqbal, Li Xiao, et al.
British Journal of Haematology|October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphomaRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
American Journal of Hematology|June 17, 2026
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell LymphomaStephen D Smith, Suchitra Sundaram, Sharmila Giri, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 24, 2025
Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell LymphomaCarrie Ho, Neena Kennedy, Mengyang Di, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 28, 2020
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell LymphomaSolomon A Graf, Ryan D Cassaday, Karolyn Morris, et al.
JCO Oncology Practice|November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World ExperienceIvan J Huang, Grace T Baek, Jonathan Cohen, et al.
Pageof 8